Archive for the ‘Bone Marrow Stem Cells’ Category

Bone marrow transplantation, also referred as hematopoietic stem cell transplantation is the process of replacing diseased or damaged bone marrow or bone marrow stem cells with healthy tissue. Bone marrow is a soft vascular tissue present in the interior of long bones, which is primarily responsible for hematopoiesis (formation of blood cells), production of lymphocytes, and storage of a fat. Bone marrow transplantation procedure is recommended to treat severe stages of leukemia, Hodgkin and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia etc. In 2015, more than 75,000 bone marrow transplants were performed globally and the count is expected to increase by approximately 25% by the end of 2020. Depending on the source of bone marrow or stem cells, bone marrow transplant procedures are classified as peripheral stem cell transplant (PSCT) or conventional bone marrow transplant. The high potential of the bone marrow transplants and the ongoing researches in the field to reduce the risks and side effects of the procedure will take the market to a new high and provide better healthcare to millions of people in the world.

Bone Marrow Transplant Market: Drivers and Restraints, Segmentation, Overview, Region wise Overview and Key Players

Increasing worldwide prevalence of cancers and anemia is the major driver for the growth of global bone marrow transplant market. Moreover, advances in technology, improving healthcare infrastructure, emerging indications of bone marrow transplant for heart and neuronal disorders, growing investment in logistic services, increasing per capita healthcare expenditure are some other factors expected to flourish the global bone marrow transplantation market. However, tremendous cost of the treatment, scarcity of bone marrow donors and uncertainty of reimbursement in several countries are some major restraints for the growth of global bone marrow transplantation market,

The global bone marrow transplant market has been classified on the basis of transplant type, disease indication, end user and geography. Based on transplant type, the global bone marrow transplant market is divided into following: Autologous Bone Marrow Transplant, Allogeneic Bone marrow Transplant; Based on the disease indication, the global bone marrow transplant market is divided into following: Leukemia, Lymphoma, Myeloma, Others (anemia, thalassemia etc.); Based on the end user type, the global bone marrow transplant market is divided into following: Hospitals, Multispecialty Clinics, Ambulatory Surgical Centers

Autologous bone marrow transplant segment of transplant type is expected to hold the major share in the global bone marrow transplant market owing to low treatment cost and high success rate. Leukemia being the most potential disease eligible for bone marrow transplant, is anticipated to contribute highest share in the global bone marrow transplant market. Hospital end user segment contributes major market share in global bone marrow transplant market owing to the requirement for advanced healthcare infrastructure for the procedure. Commercialization of stem cell therapies and expansion of them for clinical use is anticipated to cause surge in global bone marrow transplant market over the forecast period of 2016-2026.

Geographically, global bone marrow transplant market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.Europe will continue to lead the global bone marrow transplant market due to high density of bone marrow transplant centers and expanding bone marrow registries. Latin America is anticipated to witness rapid increase in volume of bone marrow transplant market owing to high number of potential candidates for the procedure. Increasing number of bone marrow transplant teams in North America is foreseen to boost the bone marrow transplant market in the region.

Some of the key players in global bone marrow transplant market are Lonza Group Ltd., Merck Millipore Corporation, Sanofi-Aventis LLC., AllCells LLC., STEMCELL Technologies, ATCC Inc., Hemacare Corporation, Cellular Dynamics International, ReachBio LLC., Conversant Bio, abm Inc., PromoCell GmbH, Cruline Human biospecime PRO, Lifeline Cell Technology, Mesoblast Ltd. and others.

Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1354

Market Intelligence Report Small Animal Imaging, 2016 to 2026

Anticonvulsants Market Latest Innovations, Drivers and Industry Key Events 2016 2026

Link:
Bone Marrow Transplant Market Figures and Analytical Insights 2016 2026 - LANews By Abhishek Budholiya (press release) (blog)

By Nick Mordowanec

Kathy Gianotti talks with Ottawa Elementary teacher Brad Everett about becoming a donor June 6 at Cheyenne Elementary School. (Photo by Donna Agusti)

Posted June 20, 2017

click to enlarge

Michelle Habedank, a kindergarten teacher at Cheyenne Elementary, finishes swabbing. (Photo by Donna Agusti)

Michelle Habedank, a kindergarten teacher at Cheyenne Elementary, finishes swabbing. (Photo by Donna Agusti)

MACOMB TOWNSHIP Its as simple as a cheek swab.

On June 6, Cheyenne Elementary School, of Chippewa Valley Schools, partnered with international nonprofit organization DKMS to host a bone marrow registration drive to catalog potential lifesaving donors.

A reported 70 individuals were registered during the drive, which lasted five hours.

Kelly Gianotti, a third-grade teacher at the school, helped bring the first drive of its kind to Cheyenne after experiencing firsthand the whirlwind of emotions that comes from essentially saving another persons life.

In 2013, Gianotti was in her local gym when she saw a flyer about a local high school student who needed a donor. She was so intrigued in the prospect of helping someone else that she registered almost immediately.

The process was easy, she said. She registered by swabbing her cheek with a Q-tip-like device, which entered her into a national database of potential donors. Whenever a patient is diagnosed with a blood disease but whose body rejects treatment, the bone marrow database may be the intermediary between life and death.

Its a timed process, Gianotti explained, as patients receiving bone marrow must first go through chemotherapy.

The actual donation portion of the marrow takes place in one of two ways.

One way is through the peripheral blood stem cell, which essentially takes blood out of one arm, a machine extracts the stem cells, and blood is inserted back into the other arm to regenerate the healthy marrow in the body. It has about a 75 percent success rate.

The other method involves extracting marrow from the hip bone, which is a longer procedure that requires general anesthesia and will lead to more physical soreness. That method is usually suggested for patients under 3 years old.

About one year after swabbing her cheek, Gianotti was found to be a match for a woman in her early 60s from Boston. After completing blood work and getting a physical, Gianotti was able to donate by giving stem cells via her arms.

It cured her blood disease that she had, so it saved her life and gave her extra years, Gianotti said.

Amanda Schamper, recruitment coordinator for DKMS, said there are 7.4 million donors in the DKMS database. The organization, which was founded about 25 years ago, has offices in the United States, Germany, Spain, the United Kingdom and more.

Schamper said that 170,000 Americans are diagnosed with blood cancer every year, with nearly 14,000 of those people requiring bone marrow or stem cell transplants. Less than half cant get the transplant, though, because there arent enough donors. Only four in 10 individuals find a match.

A donor could realistically alter the effects of blood cancer and approximately 70 other different types of diseases.

Only about 2 percent of the U.S. population is part of the registry a number that has stayed stagnant, though awareness is increasing. A lot of it has to do with ethnicity, she said, as the same ancestries tend to find better matches. For example, Caucasians tend to find more matches because there are more Caucasians on the registry. Its admittedly not very diverse.

In order to be a donor, DKMS first looks at eligibility requirements such as if a person is healthy, and if he or she understands the donation process.

As you can imagine, it would be devastating for a patient and family if someone backs out at the last minute, Schamper said. That actually does happen.

Once the 30-second cheek swab is complete, a person is added in the database and stays there until the age of 61. People between 18 and 55 years old are eligible to register.

Success rates are then acknowledged on personal levels. The cutoff of 61 years is due to the health and safety of the donor, as mutations occur in DNA and pose a greater risk of complications afterward. Also, the safety and urgency of the patient is essential.

To summarize, donors offer healthy stem cells to patients whose stem cells are abnormal in the bone marrow and cease to function. It affects the immune system, along with white and red blood cells.

Like Gianotti, Schamper has her own personal story. While pregnant with her third child, a boy, and working as a registered nurse in Illinois, Schamper was diagnosed with leukemia.

Her sisters blood wasnt a match, which wasnt a big surprise as only 30 percent of patients can find familial matches. She was given blood from a donor, which saved her life and inspired her own mission to help others.

My donor saved my life, she said. Im very lucky they were able to find one.

Gianotti said she would donate again in a heartbeat. Whether or not Cheyenne will hold another drive next year is unknown, but the fact that 70 people were added to a database in one evening gives her encouragement.

To me, its just important because its a very easy procedure and an easy process, Gianotti said. People always have something on their bucket (list), like, I want to save a life or Do something for someone else. This is a simple way to do that.

Its a rewarding experience, and I talk to (the Boston patients) family and theyre so appreciative of it. I always say to treat people like you want to be treated.

To learn how to become a donor, visit http://www.dkms.org.

About the author

Nick Mordowanec covers Fraser, Clinton Township, Fraser Public Schools, Clintondale Community Schools and Baker College for the Fraser-Clinton Chronicle. Nick, a graduate of Michigan State University, has worked for C & G Newspapers since 2013 and has won awards from the Society of Professional Journalists Detroit Chapter and the Michigan Press Association. He has slight obsessions with Seinfeld and Led Zeppelin.

Full bio and more articles by this reporter

For more local news coverage, see the following newspapers:

Read more here:
School, nonprofit team up to register blood disease donors - C&G Newspapers

For two decades it has been helping to change the lives of hundreds of patients.

Now the Bone Marrow Transplant Unit at Singleton Hospital is marking its 20th anniversary with an 800,000 expansion.

The unit was established after a campaign from patients who previously had to travel to Cardiff for treatment and in 2011 it came together with Cardiff to allow more people in Swansea to receive bone marrow transplants than ever before.

There were fewer than ten transplants taking place a year in Swansea in 1997 but since 2011 this has risen to 30 a year.

The Welsh Health Specialised Services Committee, which commissions the BMT service, has now approved increasing this to 50 a year.

It also approved a 793,000 investment for an expansion of the Singleton BMT unit, which will include new facilities such as extra cubicles as well as additional specialist staff.

Dr Al-Ismail said: It started as very much a local service for Swansea and Neath Port Talbot and has now moved to a regional service, which means we can treat more people than ever before.

Among the almost 300 patients who have been cared for in the BMT unit is Keith Pearman from Llanelli .

Keith was diagnosed with Non-Hodgkins Lymphoma in February 1994, just 15 months after tying the knot with wife Karen.

He underwent several courses of chemotherapy in Singleton Hospital and had periods of remission over the following six years.

But in 2001 the disease returned with a vengeance, requiring aggressive chemotherapy followed by bone marrow transplant using Keiths bone marrow stem cells, which had been harvested and frozen years before.

During a celebration to mark the Singleton units 20th anniversary, Keith said: The fact that Im here talking to you now is testament to the unit and all the staff involved.

It cannot be an easy place to work. All the staff there, every single person involved, I cannot praise them or thank them enough. They saved my life.

A stem cell (bone marrow) transplant involves replacing damaged blood cells with healthy ones. Its used to treat a range of conditions affecting blood cells such as lymphoma and leukaemia.

The high-dose chemotherapy damages the bone marrow, leaving the patient highly vulnerable to infection until the transplanted stem cells have had time to repair this damage.

Stem cell harvesting is done in Cardiff in one day but the transplants take place in the Singleton unit, which has all the necessary facilities, involving an inpatient stay of around three weeks.

But pre-1997, patients from Swansea and South West Wales not only had the harvesting but the transplant carried out in Cardiff.

Since starting in 1997, the unit has treated hundreds of and some of them, along with past and present staff and others involved in the services development, attended a special anniversary lunch.

Consultant haematologist Dr Saad Al-Ismail, who leads the service at Singleton , said: Patients couldnt understand why they had to spend three weeks in Cardiff. We were already treating the diseases. We had the nursing and medical expertise. So adding bone marrow transplantation was not a big undertaking.

Meanwhile, Cardiff was struggling to meet the demand from across South Wales. Patients were waiting for beds to have transplants, and often their condition deteriorated while they were waiting.

Dr Al-Ismail said: The demand was for the service to expand. But Cardiff could not expand so Swansea was the obvious choice.

Visit link:
Hospital unit where lives have been changed set for massive expansion - WalesOnline

The Jerusalem Post

Ex-Hadassah head of bone-marrow transplants loses license for 6 months The Jerusalem Post The Health Ministry suspended for at least six months the license of Prof. Shimon Slavin, the much-celebratad former head of bone-marrow transplantation at Hadassah University Medical Center, who retired in 2007 and set up a private clinic in Tel Aviv.

Go here to see the original:
Ex-Hadassah head of bone-marrow transplants loses license for 6 months - The Jerusalem Post

Frances Wang, KXTV 12:07 AM. PDT June 18, 2017

Dawson Deschaine, 8, of Nevada County, passed away after a long battle with leukemia. His family hopes to bring the 'Beads of Courage' program into more hospitals as part of Dawson's legacy.

While most kids try to earn gold stars for their work, Dawson Deschainefelt a little pride every time he earned a bead.

"The Beads of Courage program is these beads that [represent] every poke, every hospital stay, every bone marrow biopsy, every chemotherapy," said Breanna Deschaine, Dawson's mother.

Dawson was diagnosed with leukemia in January 2015 at just 6-years-old. The battle would last two-and-a-half years. It was all Dawson ever knew.

"He mostly knew nurses, doctors, family," said Jason Deschaine, Dawson's father. "He had a lot more adult conversations than kid ones."

Breanna said he was an old soul. He even drank a cup of coffee every morning (decaf, of course).

"They accidentally sent him coffee [instead of hot chocolate] to his room one day," said Breanna.

Dawson's mom said he was an old soul. After getting coffee instead of hot chocolate, that's what he drank every morning (decaf, of course). pic.twitter.com/eYx7Ed57XX

Dawson battled leukemia for 2-and-a half years. Smiled through it all. Chemo, stem cell transplanted, bone marrow biopsies... pic.twitter.com/NN5NoFSFLI

Now you know an infectious smile like Dawson's comes with some pretty funny stories.

Last August, Nevada County made Dawson an honorary firefighter. They called it 'Dawson Day' with a ceremony and all.

Sweet Dawson passed away this Sat. after battling leukemia. He was only 8 years old. Last yr, he became an honorary Nevada Co. firefighter. pic.twitter.com/RkVOY0WGhD

Dawson was given a badge, his own turnouts, and boots. He even got to respond to an injured biker.

"He kept telling the EMTs how to wrap the leg!" said Breanna.

And his firefighter card, he never took for granted.

"He was getting ready to go to clinic one day," said Jason. "He comes back running in the house saying 'I need my ID Card!'...'No no, I need it. Just in case mom gets pulled over, [I can say police officer,] I am with the fire department.

It's reminiscing and laughing about stories like this that keep his family strong and smiling even when it hurts.

"People always ask how we're doing. As you can tell we smile. Dawson would never let us cry in the room," said Breanna.

Dawson's community made sure his last months in this world was full of adventure. Sadly, he got too sick for his Make-A-Wish: to go to Hawaii and swim with dolphins.

Dawson had plenty of adventures his last 6 months. Sadly, he never got to swim with dolphins in Hawaii... it was his dream . pic.twitter.com/UQeAqIwzW3

On June 10th at 6:05 AM, with his parents and his sister by his side, Dawson passed away.

Even up until his very last moment, he gave his family a thumbs up.

"He couldn't talk very much. Just the thumbs up that he was still good. He was Awesome Dawson," said Breanna, through tears. "It was his signature. No matter what...I told him 'It's OK Dawson. You fought the hardest battle and you won.'"

"You're not supposed to cry!" said Melody, Dawson's grandmother. "He's watching you."

And if Dawson was watching, what would they say?

"I would say thank you, for the opportunity...you pulled our community together and made our family so strong," said Melody. "We all love him very, very much. And miss him."

Breanna said she would read to him again from his favorite book 'Love You Forever.'

"His favorite saying from his favorite book: 'I love you forever. I like you for always. As long as I'm living, my baby you'll be," said Breanna.

Dawson's family hopes to continue his legacy by bringing the Beads of Courage program that got him through his darkest days into more hospitals.

Donations can be made on the Beads of Couragewebsite, under Dawson's name.

And until they see Dawson again, the family says they'll live by this motto: 'Don't cry because it's over. Smile because it happened.'

That is what Dawson would've wanted.

2017 KXTV-TV

See the rest here:
Awesome Dawson: The legacy an 8-year-old boy who battled leukemia leaves behind - ABC10

Asian American Donor Program encourages minorities and mixed heritage to join national registry

Oakland Lisa Marie Evangelista, a 31-year-old Filipina woman who lives in Sacramento, is in a literal fight for her life. Lisa is a speech language pathologist and works at the U.C. Davis Medical Center.

On Dec. 27, 2016, she was diagnosed with Chronic Myelomonocytic Leukemia, a rare and aggressive blood cancer. She needs a bone marrow transplant to survive. Lisas sister is a 5/10 or half match. However, doctors prefer Lisa find a 10/10-donor match. To find a perfect match, Lisa needs a stranger to step forward and help save her life.

Lisa has partnered with the Asian American Donor Program to find a donor similar to her genetic makeup. A bone marrow transplant, which is needed soon, is Lisas only hope for her long-term survival. A committed 10/10 marrow-matching donor must be located to have a successful transplant. Since Lisa is of Filipino, a matching donor will also need to be of Filipino or Asian descent.

More about Lisa

Lisa learned about her diagnosis just nine months after her father died of a blood cancer. Family and friends note how she brings laughter, joy, warmth, and kindness to each day. Lisa is a speech-language pathologist and board certified specialist in swallowing and swallowing disorders. Her clinical interests include the evaluation and treatment of dysphagia resulting from radiation and chemotherapy treatments to the head and neck. She works directly with patients diagnosed with throat cancer. Lisa has lectured at the regional and national levels on pulmonary health and ethical considerations in dysphagia management. Lisa is described by her colleagues as a brilliant clinician and scientific thinker who is devoted to helping her patients. Lisas hobbies include traveling, hiking, and dancing.

Lisa grew up in Laguna Hills in Orange County, California. She attended Laguna Hills High School. From California State University, FresnoLisa received abachelors degree in 2007 and a masters degree in 2009. Lisa received her clinical science doctorate in medical speech-language pathology from the University of Pittsburgh, Pittsburgh, PA in 2014.

Whats the solution?

Minorities are more likely to die of leukemia and other blood cancers because there is a shortage of ethnic and mixed-ethnic donors on the Be The Match national registry. It is vital to expand and build a more diverse registry so everyone has an equal opportunity to survive blood cancers.

Encouraging more people of ethnically diverse backgrounds and those of mixed heritage to be committed and join the Registry, potentially saving a life. Each of us can Be TheOne to Save a Life!

The Asian American Donor Program (AADP,www.aadp.org) is a 27-year-old nonprofit organization, based in Alameda, CA, that works to educate community members about the shortage of ethnic marrow donors and the importance of joining the Be The Match national registry. It is the oldest nonprofit of its kind in the country. AADP staffis dedicated to increasing the availability of potential stem cell donors for patients with life threatening diseases curable by a blood stem cell or marrow transplant.AADP is an official recruitment center for Be The Match.

There is a shortage of committed non-Caucasians on the Be The Match national registry, says Carol Gillespie, the AADP executive director. We need everyone of mixed race ancestry to step forward and join the Registry.When a marrow match is not readily available, patients have to wait longer than is ideal to find a match.Once a match has been found, their disease may have progressed to the point that they are no longer eligible for a transplant.

Shortage of ethnic/multi-ethnic donors

Approximately every three minutes one person in the United States is diagnosed with a blood cancer. An estimated combined total of 172,910 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2017. New cases of leukemia, lymphoma and myeloma are expected to account for 10.2 percent of the estimated 1,688,780 new cancer cases diagnosed in the U.S. in 2017. (From:http://www.lls.org/http%3A/llsorg.prod.acquia-sites.com/facts-and-statistics/facts-and-statistics-overview/facts-and-statistics)

Of the approximately 816,000 Asians on the Be the Match registry, .5 percent are Filipinos, while Filipino Americans constitute 19.7 percent of Asian Americans (Source: 2010 Census). The Be The Match registry recruits hundreds of thousands of donors each year through an extensive network of more than 155 local and regional Community Engagement Representatives and organizations. You only need to join the Be The Match registry once.

Finding a marrow/stem cell match can be like finding a needle in a haystack, says Gillespie. Multi-racial patients face the worst odds. Those diagnosed with a blood disease need a marrow/stem cell transplant as soon as possible. Building the Registry with committed donors is what patients need. You could potentially match anyone in the world, this is truly a global effort.

Marrow/stem cell matches are very different than blood type matches. Just as we inherit our eyes, hair, and skin color, we inherit our marrow and stem cell tissue type.

For thousands of severely ill blood cancer patients, there is a cure, Gillespie says. You could be the cure. Those whose marrow/stem cells are not a match for a patient in need now may be a match for someone else down the road, anywhere in the world. I encourage multi-ethnic individuals to commit to registering. It is simple to register just a swab of the inside of your cheek.

How you can commit to help

Find a registration drive in your area. Go tohttp://www.aadp.org/drive/.

Register on line here:https://join.bethematch.org/lisa.

You must be 18 to 44 years old and meet general health requirements

Fill out a consent form and do a cheek swab.

Be committed. Be ready to donate to any patient in need.

Contact friends/family and encourage them to go to a registration drive or register online.

Set up a drive in your area or for more information, call AADP at 1-800-593-6667 or visit our websitehttp://www.aadp.org.

Volunteer to help at registration drives.

Please take a few minutes of your time to learn more about how you can help save a life and register as a marrow donor.

Upcoming registration drive

Soy and Tofu Festival, Saturday, June 17 from 11 a.m. to 5 p.m. Open to the public at Saint Marys Cathedral,1111 Gough St., San Francisco, CA 94109.

Malayan SF Outdoor Festival, Philippine Independence Day, Sunday, June 18 from noon to 8 p.m. at Union Square, 333 Post St., San Francisco, 94102.

More about the Asian American Donor Program (AADP)

The Asian American Donor Program (AADP), with its offices in the San Francisco Bay Area,is dedicated to increasing the availability of potential stem cell donors for patients with life threatening diseases curable by a blood stem cell or marrow transplant.

AADP is a community-based nonprofit for social benefit (5013) organization and specializes in conducting outreach and donor registration drives in and with diverse communities. AADP is an official recruitment center of the Be TheMatchregistry.

To learn more about scheduled upcoming marrow drives, visithttp://www.aadp.org/drive/.

Here is the original post:
Filipina urgently needs bone marrow donor - Asianjournal.com

MUMBAI: Three-year-old Kinaya Shah was diagnosed with thalassemia at the tender age of three months and has been undergoing regular blood transfusions ever since. The only cure for thalassemia is a bone marrow transplant (BMT), a form of stem cell therapy. Typically, the donor of the stem cells would be a sibling of the patient such that the stem cells of the donor are a near perfect match to those of the patient. The only complication was that Kinaya was a lone child.

So, city doctors in a first used stem cells donated by Kinaya's father - who was only a half or haploidentical match - to cure the child of the blood disorder. "We went to Vellore, Bangalore and Pune but no one was willing to do the transplant without a full match donor," said Kinaya's parents, Aneri and Shripal Shah. They approached Dr Santanu Sen at the Kokilaben Dhirubhai Ambani Hospital, Andheri, in October of 2016, after reading about a similar surgery that he had performed.

While haploidentical bone marrow transplants are carried out to cure leukaemia, it has only been done about half a dozen times for thalassemia in a couple of Indian cities. ``Haploidentical transplants are gradually increasing because of better techniques,'' said Dr Sen.

Dr Sen has completed 36 BMTs in the last two years, of which 12 were haploidentical donors. ``But this is the first time that a haploidentical transplant has been done in western India to cure thalassemia,'' he said.

Chennai-based haematologist Dr Revathy Raja said that there is a 85% chance of cure in thalassemia with a fully matched donor. ``The success rate falls to 70% with a half-match or haploidentical donor. We have hence not started it at our Chennai centre. Hopefully, techniques will further improve in the coming years,'' she said.

In order to perform the surgery, Dr Sen conditioned Kinaya's immune system over three months, with slight chemotherapy, to increase the chances of her body accepting the graft. "We found that her father's stem cells were a 70% match through genetic tests and decided to use them for the transplant. In the case that the graft was rejected we froze a couple of Kinaya's stem cells as insurance. The positive is that children have lower rejection rates for foreign cells as they have barely developed any active immunity," said Dr Sen. "BMT is the most viable treatment to cure thalassemia, the only barrier thus far was the necessity of a full match donor," he added.

However, Vinay Shetty of NGO Think Foundation, which works for thalassemia patients, said that it would be prudent to wait for a statistically significant number of successful halploidentical transplants before recommending it to all patients.

Post the three months of conditioning, stem cells were collected from her father's bone marrow and the transplant was performed on May 10, 2017. After several tests to confirm that the graft was accepted, Kinaya was finally discharged from the hospital on June 13.

"The future of thalassemia treatment probably lies in gene therapy, but at the moment, haploidentical transplants have made BMT much more accessible," said Dr Sen, adding that he has two more cases such as Kinaya lined up. Kinaya is expected to be completely independent of medication and any trace of thalassemia in the coming six months.

What is Thalassemia?

Thalassemia is a genetic blood disorder when the body produces abnormal hemoglobin. Patients require regular blood transplant and well as dietary control to ensure that blood irons level stay suppressed.

Read more here:
In a first, Mumbai doctors use dad's cells to fight blood disorder - Times of India

Cell harvesting is a technique of collecting stem cells for regenerate, transplant or repair the damaged organ with healthy functioning ones. Cell harvesting is considered as an important step in biopharmaceutical manufacturing industry that can directly affect the product quality and related downstream processes. Stem cells harvesting helps in treating with diseases namely cancers, blood disorders, immune deficiency diseases and various injuries. This therapy is also beneficial for burn victims which help them in grafting new skin cells as a replacement for damaged ones. Many companies are focusing on regeneration of myocardial tissue by injection of cell graft consist of adult stem cells from the patients for manufacturing regenerating medicines. For the treatment of eye diseases new healthy cells are also be grown. For harvesting bone marrow a companies are manufacturing devices with passive flexible drilling unit and suction mechanism which will help in reducing the invasiveness of bone marrow transplantation. Cell harvesting system helps in reducing the invasiveness of bone marrow aspiration from the iliac bone with less punctures. Moreover, helps in reducing procedure time and contamination by T-cells.

Cell Harvesting Systems Market:Drivers and Restraints, Segmentation, Overview, Region-wise Outlook and Key Players

Cell Harvesting Systems Market are witnessing maximum growth owing to increase bone marrow transplantation procedures attributed to high prevalence of blood cancer and anemia. Moreover, improving healthcare expenditure, survival rate after treatment, increasing investment in logistic services, expansion bone marrow transplant registry for heart along with neuronal disorders and growing per capita healthcare expenditure. However, high cost of cumbersome treatment, lack of reimbursement policies, immunological rejection, viable cell density, and identification of stem cells in adult tissues, and complications during cell harvesting and inadequate number of HSCs cells for transplantation is a major barrier to the cell harvesting systems market.

The cell harvesting systems market has been classified on the basis of techniques, application and end user. Based on techniques, the cell harvesting systems market is segmented into the following: Altered Nuclear Transfer, Blastomere Extraction; Based on application, the cell harvesting systems market is segmented into the following: Bone Marrow, Peripheral Blood, Umbilical Cord Blood, Adipose Tissue; Based on end-user, the cell harvesting systems market is segmented into the following: Research Centers, Academics Institutes, Diagnostic Labs, Hospitals

Cell harvesting systems market witnessed substantial growth owing to equipment efficacy and accuracy during stem cells harvest. By application type, bone marrow aspiration is anticipated to hold the major share in the cell harvesting systems market owing to less process error, safe and simple procedure and less side effects. People suffering from Leukemia eligible for bone marrow transplant, is expected to contribute highest share in the global cell harvesting systems market. Cell harvesting systems helps in enhancing proper pigmentation in scar reconstruction which encourage companies for continuous technology advancement in both cell isolation techniques and downstream purification processes.

Depending on geographic region, cell harvesting systems marketis segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. Asia Pacific dominates the cell harvesting systems marketfollowed by Europe, Japan and North America owing to high concentration of bone marrow stem cells harvesting centers and registries along with skilled doctors for the process of harvesting stem cells in these regions. Asia Pacific, Middle East and Africa hold huge potential and shows substantial growth in terms of wide acceptance of new technologyowing to awareness among population, increasing healthcare expenditure along with high number of potential candidate for the procedure.

Key players of cell harvesting systems market are PerkinElmer Inc.Tomtec, Bertin Technologies, TERUMO BCT, INC., hynoDent AG, Avita Medical, Argos Technologies, Inc., SP Scienceware, Teleflex Incorporated., Arthrex, Inc., Thomas Scientific, BRAND GMBH

Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1754

Blood Fluid Warming System Market Volume Forecast and Value Chain Analysis 2016-2026

Aptamers Market Dynamics, Forecast, Analysis and Supply Demand 2016-2026

Read the original here:
Cell Harvesting Systems Market Analysis, Segments, Growth and Value Chain 2016-2026 - LANews By Abhishek Budholiya (press release) (blog)

Newswise You might think stem cells only exist inside a fetus, but your adult body has a stockpile of stem cells, armed and ready to respond. These remarkable cells can develop into any other type of cell, like muscle or bone or nerve cells.

Researchers know heart attacks and strokes summon these cells. They flock to your heart or brain from all over your body to help you stay alive.

But, scientists did not realize other injuries, like a torn ACL of the knee, could command the army of stem cells to deploy.

Kevin Baker, Ph.D., Beaumont director of Orthopedic Research, conducted a study with Beaumont orthopedic surgeon Kyle Anderson, M.D., and others that revealed ACL tears send a signal to stem cells throughout our body.

After an ACL tear, Dr. Baker and his colleagues found a six-fold increase in stem cells circulating around the knee, similar to the bodys response to a major, life-threatening event like a stroke or heart attack.

However, when the stem cells arrive to help regenerate and repair the injured ligament, they get stuck. They cant get through the thick membrane that surrounds the knee joint.

We think this discovery will help us to understand how the body responds to an ACL injury, and also how post-traumatic osteoarthritis develops after a joint injury, Dr. Anderson said.

Post-traumatic osteoarthritis is a form of arthritis that develops after a knee injury. Its a common injury that affects veterans, athletes and anyone who puts stress and strain on their knees. But, until now, little was known about how the body attempts to heal these injuries.

As we age, the number of stem cells in our body declines. This could explain why your knee joint doesnt heal as well after a trauma when you are older, Dr. Baker said.

Osteoarthritis affects more than 30 million adults in the United States, according to the Centers for Disease Control and Prevention, and many of these cases occur after trauma to a joint. Its also a leading cause of disability.

The next step of our research will be finding methods to get the stem cells inside the joint. If the stem cells can get through the membrane around the knee, they could help speed up the healing process and perhaps delay or prevent arthritis, Dr. Baker added.

The study, funded in part by the American Orthopedic Society of Sports Medicine, is entitled, Acute mobilization and migration of bone marrow-derived stem cells following anterior cruciate ligament rupture. The authors believe it is the first study of its kind to reveal the bodys systemic stem cell response to an ACL injury.

Dr. Baker and Dr. Andersons research will appear in an upcoming edition of the journal Osteoarthritis and Cartilage. Other members of the research team are Perry Altman, M.D., Beaumont orthopaedic surgery resident, as well as Asheesh Bedi, M.D., and Tristan Maerz, Ph.D., of the University of Michigan.

View original post here:
Researchers Discover Body's Stem Cell Army Hits a Wall When Responding to an ACL Injury - Newswise (press release)

Back to Browse Journals International Journal of Women's Health Volume 9

Ahmed Badawy,1 Mohamed A Sobh,2 Mohamed Ahdy,3 Mohamed Sayed Abdelhafez1

1Department of Obstetrics and Gynecology, 2Department of Internal Medicine, 3Department of Clinical Pharmacology, Mansoura University, Mansoura, Egypt

Objective: Attempting in vivo healing of cyclophosphamide-induced ovarian insufficiency in a mouse model using bone marrow mesenchymal stem cells (BMMSCs). Methods: Female BALB/c white mice were used to prepare a model for premature ovarian failure by single intraperitoneal injection of cyclophosphamide (80 mg/kg). Ten mice were injected with BMMSCs and then sacrificed after 21 days for morphometric evaluation of the ovaries. Hormonal profile was evaluated while mice were being sacrificed. Another 10 mice were left for natural breeding with male mice, and 5 of these were injected with BMMSCs. Oocyte-like structures were obtained from 3 mice and were subjected to in vitro fertilization/intracytoplasmic sperm injection. Results: Morphometric analysis of the ovaries demonstrated the presence of newly formed primordial follicles. Contribution of MSCs to the formation of these follicles was proven by a labeling technique. There was a drop in estradiol and rise in follicle-stimulating hormone levels, followed by resumption of the hormonal levels to near normal 21 days after MSCs therapy. The 5 mice that were injected with MSCs became pregnant after natural breeding. Fertilization and further division was reported in 5 oocytes subjected to intracytoplasmic sperm injection, but division did not continue. Conclusion: From this proof-of-concept trial, we can say that healing of damaged ovaries after chemotherapy in mice is possible using in vivo therapy with BMMSCs. This should open the gate for a series of animal studies that test the possibility of in vitro maturation of germinal epithelium of the ovary into mature oocytes.

Keywords: cyclophosphamide, stem cell, POF, ovarian insufficiency

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to read the rest:
Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model - Dove Medical Press

Dr. Keith Roach, Syndicated Columnist

DEAR DR. ROACH: I hope you can answer some questions about myelodysplastic syndrome. What does it do to your body? Is there a known cause or cure? What is the prognosis? P.B. ANSWER: The myelodysplastic syndromes are a group of similar diseases, specific types of blood cancers, that prevent your bone marrow from working properly. They also can transform into acute leukemia. These are uncommon cancers, with perhaps 30,000 cases per year in the U.S. The specific myelodysplastic syndromes are now categorized by appearance, genetic abnormalities of the cells, and condition of the bone marrow.

MDS may arise from damage to DNA, such as from radiation or other toxic exposures. However, many cases have no known cause, and its likely that these are spontaneous mutations in the bone marrow cells.

Because MDS is a group of related diseases, the treatment and prognosis vary among the different subtypes. However, supporting the bone marrow with transfusions of red blood cells and platelets often is necessary. Medications to stimulate both red and white blood cell production can be used. A few people will be recommended for bone marrow (stem cell) transplant, but the decision to consider this treatment must be made cautiously, as many people who get MDS will not benefit from this treatment due to age or other medical conditions.

The prognosis depends on the age of the person affected and their specific MDS. A person younger than 60 with a low-risk MDS has a median survival (based on data published in 1997) of about 12 years. However, high-risk MDS has a much worse outcome: Half of people succumb within six months. Advances in treatment since these data were published have improved these results, but not as much as hoped.

DEAR DR. ROACH: My 89-year-old mother suffers from fluttering in her heart. She saw an expert in cardiac arrhythmias, who diagnosed her with tachy-brady syndrome and sick sinus syndrome. A nurse also said she has PVCs. She is taking metoprolol, but still has episodes of fluttering. What are these conditions? Are there other medications she could take to correct this heart condition? M.D.P.

ANSWER: Tachy-brady syndrome (from the Greek roots for fast and slow) and sick sinus syndrome are the same thing. The sinus in sick sinus syndrome refers to the sino-atrial node of the heart, which is the hearts natural pacemaker. It is where every beat normally starts. This part of the heart can become diseased, and the heart can beat both too quickly (tachycardia) and, at other times, too slowly (bradycardia). Sick sinus syndrome can come from many different conditions and, rarely, from medications.

Medications are sometimes used for sick sinus syndrome. Beta blockers, like the metoprolol your mother is taking, are given to slow down the tachycardic component of sick sinus, but it can make the bradycardia worse. Most often, the treatment for sick sinus syndrome is a permanent pacemaker. Not everyone needs it, but Im sure your mothers cardiologist is monitoring her and will recommend a pacemaker if needed. If one is necessary, 89 years old is not too old to put in a pacemaker.

PVCs are very common and do not usually indicate disease in the heart, although they are more common in people with heart disease, especially poor blood flow to the heart. Premature ventricular contractions themselves seldom need treatment.

See the original post:
TO YOUR GOOD HEALTH: 'Myelodysplastic syndrome' covers a range of diseases - Prescott Daily Courier

Release from the University of Virginia Health System:

CHARLOTTESVILLE, Va., June 14, 2017 - University of Virginia Cancer Center has earned recognition as a national center of excellence for its care of patients with myelodysplastic syndrome (MDS), a cancer of the bone marrow that often leads to leukemia.

UVA is the only center in Virginia to receive this designation from the MDS Foundation for the treatment of this condition, which UVA hematologist Michael Keng, MD, said is often referred to as a bone marrow failure disorder.

Bone marrow produces stem cells that make white blood cells, red blood cells and platelets. In patients with MDS, the marrow does not produce enough healthy cells. When there are not enough healthy cells, there is an increased risk of infection, bleeding, easy bruising and anemia. Approximately 30 percent of patients diagnosed with MDS will progress to a diagnosis of acute myeloid leukemia.

According to the MDS Foundation website, centers of excellence have:

UVA provides tailored care for each MDS patient through a multidisciplinary team. UVAs care team includes medical oncologists/hematologists, pharmacists, care coordinators, nurses, infectious diseases specialists, clinical trial coordinators, and support services such as social workers, case workers, and therapists.

UVA is devoted to providing support, research, treatment and education around MDS to all patients, caregivers, physicians, nurses and other healthcare providers, Keng said.

Read the original:
UVA Honored as Center of Excellence for Bone Marrow Cancer - NBC 29 News

AUSTIN, Texas -- Gov. Greg Abbott has signed a new law that allows terminally ill or those which chronic diseases receive stem cell treatments in Texas.

Stem cell therapy is the use of stem cells to treat or prevent a disease or condition, and is often patient's last hope for improvement.

Bone marrow transplant is the most widely used stem-cell therapy, and can often help those with multiple sclerosis and other diseases.

House Bill 810, which was introduced by Rep. Tan Parker, R-Flower Mound, passed in both the Texas House and Senate.

"It is easy to fall into the trap of viewing legislation as just words on a piece of paper," said Sen. Paul Bettencourt, R-Houston, the bill's sponsor in the Senate. "But for the many people who are ill with multiple sclerosis and other diseases that stem cell therapy has the hope of solving in our lifetime, I look at this bill, I look at the possibility of what can happen in the 21st Century, with Texas taking the lead on adult stem cell treatments and this bill has the potential to extend lives and make a difference for these patients."

The Texas Medical Board will be responsible for writing the rules for the treatment.

"Everyone has a zest for life. This adult stem cell treatment possibility gets government out of the way to let these new therapies flourish and give these patients hope for a future good quality of life," Bettencourt added.

The legislation takes effect Sept. 1.

-- Value of Stem Cell Therapy --

According to the National Institues of Health, stem cellshave the remarkable potential to develop into many different cell types in the body during early life and growth.

In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive.

When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Doctors say stem cells are important for living organisms for many reasons.

In the 3- to 5-day-old embryo, called ablastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lungs, skin, sperm, eggs and other tissues.

In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease.

---

Join the Discussion:

Follow Spectrum News Austin on Facebook | Twitter | Instagram

Link:
Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments - Spectrum News

Fat doesn't just sit on top of your bones according to recent research it can also be found inside of your bone marrow too, and running can help shrink it.

According to Dr. Maya Styner, the study's lead researcher and an assistant professor of endocrinology and metabolism at the University of North Carolina at Chapel Hill, exercise has the ability to improve bone quality, particularly in obese mice.

Though the research on mice is not directly translated to human results, Styner says, "The kinds of stem cells that produce bone and fat in mice are the same kind that produce bone and fat in humans."

Marrow is the spongy tissue found inside some of your bones and is comprised of stem cells, nerves, blood vessels and fat. In healthy adults, bone marrow is half red and half yellow.

The yellow portion of bone marrow is used to store fats and provide sustenance required for bone function. In the event of severe blood loss or fever, yellow marrow can turn red.

Styner's study suggests that, like other types of body fat, marrow fat can be used as a source of energy.

"There's been intense interest in marrow fat because it's highly associated with states of low bone density, but scientists still haven't understood its physiologic purpose," said Styner. "We know that exercise has a profound effect on fat elsewhere in the body, and we wanted to use exercise as a tool to understand the fat in the marrow."

The study, which looked at the marrow fat in mice, found after six weeks obese mice who ran on a wheel had a significant reduction in the size of their fat cells, and in some cases appeared identical to lean mice.

"One of the main clinical implications of this research is that exercise is not just good, but amazing for bone health," said Styner. "With obesity, it seems that you get even more bone formation from exercise. Our studies of bone biomechanics show that the quality and the strength of the bone is significantly increased with exercise and even more so in the obese exercisers."

View post:
Exercise Can Help Reduce Fat Found In Bone Marrow - Huffington Post Canada

Dear Dr. Roach: I hope you can answer some questions about myelodysplastic syndrome. What does it do to your body? Is there a known cause or cure? What is the prognosis? P.B.

Dear P.B.: The myelodysplastic syndromes are a group of similar diseases, specific types of blood cancers, that prevent your bone marrow from working properly. They also can transform into acute leukemia. These are uncommon cancers, with perhaps 30,000 cases per year in the U.S. The specific myelodysplastic syndromes are now categorized by appearance, genetic abnormalities of the cells, and condition of the bone marrow.

MDS may arise from damage to DNA, such as from radiation or other toxic exposures. However, many cases have no known cause, and it's likely that these are spontaneous mutations in the bone marrow cells.

Because MDS is a group of related diseases, the treatment and prognosis vary among the different subtypes. However, supporting the bone marrow with transfusions of red blood cells and platelets often is necessary. Medications to stimulate both red and white blood cell production can be used. A few people will be recommended for bone marrow (stem cell) transplant, but the decision to consider this treatment must be made cautiously, as many people who get MDS will not benefit from this treatment due to age or other medical conditions.

Dear Dr. Roach:My 89-year-old mother suffers from ''fluttering'' in her heart. She saw an expert in cardiac arrhythmias, who diagnosed her with ''tachy-brady syndrome'' and ''sick sinus syndrome.'' A nurse also said she has PVCs. She is taking metoprolol, but still has episodes of fluttering. What are these conditions? Are there other medications she could take to correct this heart condition? M.D.P.

Dear M.D.P.:Tachy-brady syndrome (from the Greek roots for ''fast'' and ''slow'') and sick sinus syndrome are the same thing. The ''sinus'' in ''sick sinus syndrome'' refers to the sino-atrial node of the heart, which is the heart's natural pacemaker. It is where every beat normally starts. This part of the heart can become diseased, and the heart can beat both too quickly (tachycardia) and, at other times, too slowly (bradycardia).

Medications are sometimes used for sick sinus syndrome. Beta blockers, like the metoprolol your mother is taking, are given to slow down the tachycardic component of sick sinus, but it can make the bradycardia worse. Most often, the treatment for sick sinus syndrome is a permanent pacemaker.

Readers may email questions to ToYourGoodHealth@med.cornell.edu.

Go here to read the rest:
'Myelodysplastic syndrome' covers a range of diseases - Sarasota Herald-Tribune

In 15 years, LifeCell is the second stem cell bank to present its innovation (concept of 'Community Stem Cell Banking') at the 15th International Cord Blood Symposium scheduled to be held at San Diego, USA between 8th - 10th June, 2017.

Singapore - LifeCell International (India's first and the largest stem cell bank)has made an entry into global platform with their recently launched concept of 'Community Stem Cell Banking'. It is believed to be a general practice that technological advancements and new concepts from the western world and other countries percolate into the Indian market. In 15 years, LifeCell is the second stem cell bank to present its innovation at such a prestigious global platform.

Acknowledging the merit of this concept, LifeCell has been invited by AABB (formerly known as American Association of Blood Banks) to portray its recently launched concept of 'Community Stem Cell Banking' at the 15th International Cord Blood Symposium scheduled to be held at San Diego, USA between 8th - 10th June, 2017.

The International Cord Blood Symposium (ICBS) brings all the umbilical cord blood related fields of hematopoietic stem cell transplantation, banking and potential in regenerative medicine together in one interactive three-day conference where world-renowned experts in the field of cord blood will present their new innovations on advancements in the industry.

LifeCell has continuously been adding new innovations to its services. The innovative concept of 'Community Stem Cell Banking' allows access to donor stem cells within the community, thereby extending the protection of stem cells to all conditions treatable by stem cells. In addition to the child, its siblings, parents and grandparents too can access the community pool of preserved stem cells for treatments when required thereby extending the protection of stem cells to the entire family. Also, there is no limit on number of withdrawals of stem cell units from the community providing a comprehensive protection.

Mr Mayur Abhaya, CEO & Managing Director, LifeCell International said, "We are delighted with this acknowledgment for our innovations in stem cell industry. It is a prestigious moment for us being given an opportunity to present Community Stem Cell Banking in a global platform of industry leaders."

Community Stem Cell Banking will be the future of umbilical cord stem cell banking especially in a country like India where the inventory of donor stem cells or bone marrow registries of Indian ethnicity is very low at less than 1% of global inventory and hence the availability of matching donor stem cells is very low. LifeCell, with this new concept, aims to create a huge inventory of donor stem cells within the next few years, which could even exceed the global standards and this will pave way for the highest probability of finding a matching stem cell unit. Mr Vinesh Mandot, Technical Lead at LifeCell, would be presenting this innovative model in a session chaired by Dr. Frances Verter, Director of Parent's Guide to Cord Blood Foundation at the international symposium.

Follow this link:
LifeCell's Community Stem Cell Banking Receives Global Recognition - BSA bureau (press release)

Stem cells might not be a good option for your kid's sports injury Miami Herald They are seen as the body's master cells, and studies have shown these cells have the capacity to differentiate into bone, cartilage, muscle and ligament tissues. MSC cells are usually harvested from bone marrow or fat cells. Evidence from laboratory ...

Read the original here:
Stem cells might not be a good option for your kid's sports injury - Miami Herald

Dear Dr. Roach: I hope you can answer some questions about myelodysplastic syndrome. What does it do to your body? Is there a known cause or cure? What is the prognosis?

A: The myelodysplastic syndromes are a group of similar diseases, specific types of blood cancers, that prevent your bone marrow from working properly. They also can transform into acute leukemia. These are uncommon cancers, with perhaps 30,000 cases per year in the U.S. The specific myelodysplastic syndromes are now categorized by appearance, genetic abnormalities of the cells and condition of the bone marrow.

MDS may arise from damage to DNA, such as from radiation or other toxic exposures. However, many cases have no known cause, and it's likely that these are spontaneous mutations in the bone marrow cells.

Because MDS is a group of related diseases, the treatment and prognosis vary among the different subtypes. However, supporting the bone marrow with transfusions of red blood cells and platelets often is necessary. Medications to stimulate both red and white blood cell production can be used. A few people will be recommended for bone marrow (stem cell) transplant, but the decision to consider this treatment must be made cautiously, as many people who get MDS will not benefit from this treatment due to age or other medical conditions.

The prognosis depends on the age of the person affected and their specific MDS. A person younger than 60 with a low-risk MDS has a median survival (based on data published in 1997) of about 12 years. However, high-risk MDS has a much worse outcome: Half of people succumb within six months. Advances in treatment since these data were published have improved these results, but not as much as hoped.

Read more from the original source:
Dear Dr. Roach: Myelodysplastic syndromes rare - Herald & Review

Scholar finds that many citizens are comfortable with providing financial incentives to living organ donors.

Every year, the United States receives 35,000 new requests for kidney transplants. Kidney reserves, however, can supply only 17,000 procedures per year. Over time, this difference between need and supply has produced a wait list including roughly 100,000 patients hoping to receive kidneys, many of whom will die on the wait list. As a result, the time a patient is expected to remain on the wait list is less than the life expectancy of someone with kidney failure. What would it take for you to agree to donate a kidney? Direct payment? A tax incentive? Free health care coverage? A club membership guarantee that you would be the first to receive an organ if you needed it?

Nicola Lacetera, a professor at the University of Torontos Institute for Management and Innovation, has found that U.S. residents are likely to support the provision of governmental incentives directed toward living donors.

Specifically, Lacetera found that 50 percent of the over 3,000 people surveyed supported providing incentives to donors. In addition, 70 percent of participants surveyed agreed that the government should pay living donors if it were certain that doing so would increase the supply of organs.

Providing incentives would not just increase access to organs by a marginal percentage. It would eliminate the kidney transplant wait list. Economists estimate that paying donors $15,000 to $30,000 for their organs would eliminate the 100,000-person wait list within a few years.

Providing incentives to living organ donors has become a pressing policy question, with recent scientific developments rendering donation less invasive. Some countries have chosen to provide incentives to live organ donors. In Israel, for example, a live organ donor not only receives a refund for lost earnings from the time necessary for the procedure and recovery, but also receives refunds on medical and life insurance, and does not have to pay the national health tax for three years. Lacetera states that, in the United States, a federal appeals court recently concluded that it was not illegal to pay blood stem cell donors, although payment for organ donation is criminalized.

Why has the United States not adopted a new policy, like Israel?

Lacetera argues that, despite the support indicated in the survey, people are generally opposed to providing incentives to living organ donors for two reasons. First, we may be concerned with the implementation of any donation incentive program. Second, although we might support the program in theory, the thought of actually adopting one is a repugnant transaction.

In a case recently before the U.S. Court of Appeals for the Ninth Circuit, parents of children who had leukemia and other diseases that can be alleviated with bone marrow transplants sued Eric Holder, the then-U.S. Attorney General, arguing that the National Organ Transplant Act was unconstitutional in its denial of payments for bone marrow transplants.

A nonprofit organization, More Marrow Donors (MMD), which aims to pay donors for their bone marrow, joined the lawsuit. MMD proposed a program in which, through a new extraction operation, removal of the complete fatty substance of the bone marrow would not be necessary. Instead, the valuable blood stem cells from the bone marrow could be collected and separated from the rest of the blood stream. MMD sought to provide donation incentives by awarding donors $3,000 in the form of scholarships, housing allowances, or gifts to charities. In other words, the donor would not receive the funding directly. The National Organ Transplant Act, however, criminalized payment for organ donations, which included bone marrow. MMD argued that prohibiting such payments is unconstitutional.

Furthermore, Lacetera argues that we might be concerned with adverse selection in the donor incentive program. As Lacetera explains, the people who might benefit most from the incentives may also be those who would be more likely to carry transmissible diseases such as hepatitis. A system of in-kind rewards and delayed compensation, however, like MMDs proposed housing allowances, would address these concerns.

In considering whether an organ incentive program could be coercive, the court explained that Congress may have been concerned that if donors could be paid, rich patients or the medical industry might induce poor people to sell their organs, even when the transplant would create excessive medical risk, pain, or disability for the donor.

Still, effective policy and regulation could address these concerns. Lacetera argues these concerns are amenable to tradeoff thinking, in which the downsides could be weighed against the potential efficiency gains that payments may cause, such as an increase in organ supply. Lacetera found that the average respondent supported a policy in which a public agency controls payment for donations and allocation of organs if the end result is a six percent increase in the organ supply. If we such a system were unregulated, then the average respondent would want a 20 percent increase in organ supply to justify the potential downsides of such a program.

Lacetera argues the there may be deeper concerns, however. Providing financial incentives to organ donors may violate our sacred values, which Lacetera defines as principles that individuals and societies are not willing to compromise against any other form of potential gain.

The Ninth Circuit anticipated this moral revulsion. As the court observed, [p]eople tend to have an instinctive revulsion at denial of bodily integrity, particularly removal of flesh from a human being for us by another, and this revulsion is most acute with commodification of such conduct, that is, the sale of ones bodily tissue.

In the end, the court did not need to decide the broad policy questions of the legality of organ donation incentives. Instead, the court held that blood stem cells, which are extracted through the blood stream rather than the bone marrow, were not considered organs. Compensating individuals for donating their bone marrow was legal.

The Department of Health and Human Services responded to the case by announcing that it would undertake a regulatory proceeding to redefine bone marrow to include the kinds of extraction methods discussed in that case, essentially overruling the appellate courts decision.

Originally posted here:
Regulating the Kidney Club - The Regulatory Review

Comments(0)

Terminally ill TV bailiff Delroy Anglin saw first-hand the love and support from the Croydon community trying to help him as in the space of two hours more than one hundred people signed up to "save his life".

The Croydon born and bred star of Channel 5's Can't Pay We'll Take it Away was diagnosed with a rare and aggressive form off leukaemia earlier this year.

His one hope of being rid of the terminal bone blood cancer is to find a perfect match for a life-saving bone-marrow transplant.

READ MORE: Charity seeking to save life of Croydon TV star tells well-wishers - 'you can save him'

As a man of Afro-Caribbean descent, finding a match is extremely difficult the numbers of minority ethnic people on the donor register is very low.

Doctors have searched in vain on the worldwide register of stem cell (bone marrow) donors to save 56-year-old Delroy, who has called his diagnosis of acute myeloid leukaemia (AML) a "death sentence" unless a match can be found quickly.

For caucasian people with AML, the chances of finding a match for stem cells (bone marrow) are somewhere between 60% and 90%. However, for people of Afro-Caribbean people, the chances are only around 20% due to the low numbers registered to donate.

As a result the Croydon community was called on to step forward and see if there was someone in the borough who could save the dad-of-six's life.

At an event on Saturday (June 10) - which was attended by Delroy - more than 100 people signed up to the donor register in just two hours to see if their marrow would be the vital match.

The drive was for Afro-Caribbean people in particular to sign up at the event.

READ MORE: Kind local man donates 1 million to new Thornton Heath youth centre

"Delroy is always overwhelmed by the support, and he was overwhelmed by this response," said Ronke Oke, who organised the drive for donors in Croydon for charity Afro-Caribbean Leukaemia Trust (ACLT).

"More than 100 people in just two hours that's pretty good.

"We hope it can make the difference.

"We would hope any one of those people could save his life. That's why we do what we do.

"We're trying to get as many people as possible to sign up in the hope that we can find a match for Delroy, and thousands of others in his position.

"He was there with his family on the day, they all saw the support for him.

"It's amazing witnessing that support online, and at the event."

The event was held art Boxpark between 10am and 12pm and within that time there was rush to sign up to the donor register which could yield a match for a bone marrow (stem cell) transplant.

READ MORE: Missing Croydon teenager found 'safe and well'

Those who missed the event but still wish to try and help Delroy can sign on to the register by visiting the ACLT website.

View post:
More than 100 people sign donor register to try and save life of Croydon dad from Channel 5 show - Croydon Advertiser

Durham, NC (PRWEB) June 12, 2017

A new study demonstrates how an infusion of stem cells can assist in treating severe cases of aplastic anemia (AA) that do not respond to immunosuppressive therapy (IST) alone. The study, which appears in STEM CELLS Translational Medicine (SCTM), offers hope for patients with this rare disease, which occurs when the bone marrow does not produce enough blood cells to meet the bodys needs.

People with AA suffer from fatigue, frequent infections, rapid heart rate and bleeding. The more severe cases can be life threatening. While IST is accepted as the first-line treatment option for AA, 30 to 40 percent of patients with severe cases dont respond well to treatment and continue to suffer from an abnormally low level of red blood cells, white blood cells and platelets. IST therapy generally consists of anti-thymocyte globulin, which is an infusion of horse or rabbit-derived antibodies against human T cells, and the immunosuppressant medication cyclosporine.

These patients who dont respond to IST might require an allogeneic hematopoietic stem cell transplant (HSCT). However, about a third of them arent able to find a suitable donor. Also, people aged 50 and older are not eligible for transplant. Another issue with HSCT is that complications such as graft versus host disease and graft failure may occur. As such, the five-year overall survival rate of patients with severe AA that is refractory to IST is less than 60 percent.

In the SCTM study, a team of researchers led by Yan Pang, M.D., and Yang Xiao, M.D., Ph.D., of the Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, in China, wanted to learn whether bone marrow-derived mesenchymal stromal cell (BM-MSC) transfusions might help patients who did not respond to IST. The phase two clinical trial involved 74 patients at seven centers who each received four doses of stem cells over a period of four weeks. Patients with response rates after the first month continued to receive infusions.

After 12 months, our evaluations showed that the overall response rate was 28.4 percent, with 6.8 percent complete responses and 21.6 percent partial response, Dr. Xiao reported. At 17 months, the overall survival of the initial 74-patient group was 87.8 percent. Seven patients developed transitory and mild headache and fever, but no other adverse events were observed.

Our study strongly indicates that MSC infusion is a promising therapy for severe AA, but improved MSC cultures in vitro and the MSC doses need further study to maximize their therapeutic potential," added Dr. Pang.

This phase II clinical study, involving 74 patients, is significant because it suggests that a stem cell transfusion can be used to treat aplastic anemia that is non-responsive to first-line therapies. The advantages of the treatment are its safety and costs, said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

###

Click for the full article, Allogeneic bone marrow-derived mesenchymal stromal cells expanded in vitro for treatment of aplastic anemia: a multicenter phase II trial.

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 35th anniversary, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, in its 22nd year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Share article on social media or email:

Read more from the original source:
Study Shows Stem Cell Infusion Helps Treat Severe Cases of Aplastic Anemia - PR Web (press release)

Panchwati Tower on Harmu Road in Ranchi where the stem cell bank is expected to come up. (Hardeep Singh)

In what may be a game-changer for healthcare in Jharkhand, a group of doctors from Ranchi have teamed up with a Mumbai-based pioneering research firm to plan the first stem cell bank of eastern India in the state capital.

Stem cells are undifferentiated biological cells that can differentiate into specialised cells and divide to produce more stem cells. They can be transplanted routinely to treat a variety of blood and bone marrow diseases, including cancer and immune disorders, while extensive research is underway on their potential to cure neurological and muscular problems.

In short, a stem cell bank in Ranchi will allow residents to store their embryonic or adult stem cells, which can be accessed anytime to treat ailing blood relatives.

Dr Deepak Verma, a senior orthopaedic consultant in the city specialising in difficult trauma surgery, said if everything went according to plan, the stem cell bank was expected to debut at Panchwati Tower on Harmu Road in another three to six months.

Dr Verma, along with pathologist Dr Sangita Agrawal and orthopaedic surgeon Dr S.N. Yadav, will form the core team of the Rs 6.5-crore facility, which will be set up in association with stem cell banking company ReeLabs, Mumbai.

"Ranchi will boast the fifth stem cell bank in India after Mumbai, Delhi, Chennai and Ahmedabad. It will be first such facility in eastern India. We plan to establish a stem cell treatment centre and a cancer immunotherapy centre to turn Ranchi into a healthcare destination," Dr Verma told this newspaper on Sunday.

While the bank will sprawl over an area of 5,000sqft, another 6,000sqft will be reserved for the therapy centres.

Elaborating on the banking system, the doctor said stem cells would be stored in cryogenic vials at minus 176 degrees and liquid nitrogen would be used to acquire the very low temperatures.

"People wishing to use the stem bank service will have to open an account. The bank will then collect stem cells from different sources such as placenta, amniotic sac, amniotic fluid, umbilical cord blood and cord tissue, menstrual blood, dental pulp, bone marrow and peripheral blood," Dr Verma said.

To deposit the stem cells, one may have to pay Rs 45,000 to Rs 2 lakh, depending on the package chosen.

"Those who will deposit stem cells can access the same for blood relatives suffering from 110 listed diseases that cannot be treated using conservative medicines," the doctor said, adding that stem cell therapy could help in cases of leukemia, thalassemia, Alzheimer's disease, cardiovascular diseases, stroke, diabetes and cirrhosis of liver, among others.

Do you think people in the state are aware of stem cell therapy?

Tell [emailprotected]

Read more:
Bank on stem cells, gift a life - Calcutta Telegraph

islamabad - The Lipogems technology has great promise, but experts say itll take time to assess how successful the new procedure is the technology is ideal for patients with certain orthopaedic conditions, such as painful joints including the knee, ankle, or shoulder with limited range of motion. Additionally, it can be used in soft tissue defects located in tendons, ligaments, and/or muscles to improve the biologic environment, said Dr Brian Cole, professor of orthopaedic surgery, and section head of the Rush Cartilage Restoration Centre, in a press release. They are believed to help the natural regenerative processes in the body.

Hence they have earned the nickname as mini drug stores based on their ability to secrete a spectrum of bioactive molecules and support the natural regeneration of focal injuries.

Stem cells can be harvested from certain parts of the human body, most notably bone marrow and adipose tissue (fat).

Harvesting bone marrow stem cells is a significantly more invasive and time-consuming procedure that is performed using general anaesthesia.

Lipogems offers a novel approach to orthopaedic stem cell treatments by using a persons own fat.

The procedure uses a small incision into an area of subcutaneous fat, from which a quantity of fat tissue is harvested and processed by the Lipogems apparatus.

The technology itself, which really is the device that processes the fat, creates a concentration of fat that has been cleansed of all the extraneous things like red blood cells and fibrous tissues, Cole told. The concentrated stem cells within that fat tissue are then applied to the problematic joint or bone area.

Lipogems offers a streamlined procedure for stem cell treatment, but there is nothing new about the science itself.

The use of stem cells to treat a variety of conditions has been ongoing for some time now.

What were lacking is really good data at this point in the clinical setting, Cole said. There is substantial data in the laboratory suggesting that these cells may function in the way Ive described: reducing inflammation and so forth. But, we really dont have yet much in the way of good solid clinical data saying that definitively this is making a difference.

Instead, he would like those seeking orthopaedic treatment to understand that Lipogems is just one part of a much larger and more complex suite of tools used by physicians.

It has to be taken into context of all the other possible treatment options, from simply icing down a swollen ankle, to changing your daily activity, to surgery.

The unfortunate thing is that people think, well this is the solution that can be used instead of, say, a joint replacement and no longer do we need to do surgery, said Cole.

Nothing could be further from the truth.

Nonetheless, Cole and his team are still excited about the possibilities of the Lipogems procedure. Using a readily available and easily accessible substance like fat as a source of stem cells could have far-reaching implications for procedures in the future. Were optimistic and intuitively there is a good argument to be made that this is as good or better than any other source of stem cells, said Cole.

More here:
New Technology Uses Body Fat to Help Relieve Joint Pain - The Nation

Across Utah County, there are people waiting for donations, whether it is a needed organ, bone marrow or blood that will save their lives. Others have given these life-saving donations to complete strangers. Gift of Life highlights those involved in the medical donation process.

They found a perfect match for Robyn Marchant on a bone marrow registry. Robyn, a Santaquin mom with leukemia, needed a stem cell transplant if she wanted to live.

But they were never able to get ahold of the match.

That was hard, Robyn said, sitting on a couch in the Huntsman Cancer Institute in Salt Lake City, next to a window that doesnt open and wearing a paisley headscarf. That was in March, at the beginning of my search.

There were two 9/10 matches on the Be The Match bone marrow registry. Doctors preferred her brothers blood work, and they decided to do the transplant with his half match. Its their best option, even if it isnt ideal.

But a lack of a match didnt stop Robyns family from hosting six drives, including ones in Provo and Spanish Fork, and adding more than 1,200 names to the bone marrow registry. They suspect theres more who have registered to Be the Match because of her, but havent used Robyns name as the promo code to link it to her name.

They might not be able to help my daughter, but I am praying there is somebody in the country who is doing the same thing to help my girl, said Shelly Bills, Robyns mother who has organized registration drives.

If Robyns transplant doesnt take, shell need another one.

And even if she doesnt need another donor from the registry, theyre hoping the names theyve added will save someone elses life.

Theres a lot of people who have never heard of the Be the Match Registry, which in all honesty we have never heard about until this happened, and now our whole town down in Santaquin knows about it, said Kevin, Robyns husband.

Diagnosis

Robyn, mom to 9-year-old Kassidy, 6-year-old Korbin, 4-year-old McKinley and 1-year-old McKellan, is a busy woman who served as a former Relief Society president for her ward in The Church of Jesus Christ of Latter-day Saints.

She started to feel really tired at the end of January and brushed it off as being worn out from having a baby. Things started to get worse to the point where shed feel like she was going to pass out when she climbed up the stairs.

It was originally thought to be anemia, but that treatment wasnt changing anything. Then her spleen started to ache.

Kevin, a pharmacist, told Robyns doctor he suspected his wife had leukemia.

Nobody expects a 31-year-old mom of four kids to get cancer, Robyn said. We were all just so overwhelmed.

She didnt ask for percentages, and only knew she wasnt going to live without a stem cell transplant.

As the oldest, Kassidy started to piece things together. The kids, who knew a neighborhood child who died after being diagnosed with cancer, were devastated.

Our kids immediately associate cancer with death, which made it hard, Kevin said.

According to Be the Match, 70 percent of patients who need a bone marrow transplant dont have a fully matched donor in their family, and 14,000 patients a year will need a transplant for someone outside their family.

For Robyn, it wasnt supposed to be hard to find someone.

The doctors at the beginning said we wont have trouble finding you a match, Robyn said. Youre Caucasian, female, of western descent, theres tons of people out there. Well find you a match. But apparently Im one in a million because we just couldnt find one.

Finding a match

Bills woke up in the middle of the night a few weeks after Robyns diagnosis knowing she had to do something.

Even though they dont plan to hold another registration drive for a while, Bills is still handing out registration kits, and a friend started the hashtag #SwabbinForRobyn.

My mind keeps saying people are so willing, they just dont know, they dont know there is something they can do to save a life, Bills said.

Shes also encouraging people already on the registry to update their contact information so another family doesnt have the same experience theyve had.

Signing up for the registry is quick process that requires a cheek swab to add a donors tissue type to the registry. Once signed up, they will remain on the registry until they are 61 or request to be removed.

Registration can be done online at Join.BeTheMatch.org. To link the registration to Robyns name, use the promo code Robyn.

Potential donors have to be between the ages of 18 and 44 and willing to donate to any patient in need.

If a match is made, there are two ways to donate. One way is through a peripheral blood stem cell donation, a nonsurgical outpatient procedure. The other is a marrow donation, a surgical, outpatient procedure that is performed in an operating room.

Only a small percentage of people on the registry will ever be called to be a match.

As she showed up to a registration drive held in a Brigham Young University LDS stake (against advice to stay away because of her compromised immune system), Robyn was touched to see hundreds of people sign up for the registry.

She didnt know a single one of them.

These kids didnt have a clue who I was, but they were willing to do something, Robyn said.

Whats next

Robyn received her brothers transplant at the end of May. Since then, shes had side effects like diarrhea, mouth sores down her throat, insomnia and nausea.

Shell be in the hospital for a couple more weeks. After that, if the transplant isnt rejected, shell have to be constantly monitored by an adult for 100 days. If all goes well, that should be it.

Her hospital room is filled with pictures of her family and has a large window that looks out to the mountain. But for now, shes not supposed to leave the unit.

Lots of pokes and prods and illnesses, I can handle that, Robyn said. But being away from my kids is hard.

She video chats with her kids at least twice a day and reads to them from the Harry Potter books before bedtime.

Shes learning to cross-stitch. Her current project, a quote from Hogwarts Headmaster Albus Dumbledore in Harry Potter and the Prisoner of Azkaban, reminds them that happiness can be found, even in the darkest of times, if one only remembers to turn on the light.

Kevin is getting help taking care of the kids from family. On weekends, they make the drive up to Salt Lake City to visit Robyn.

For now, theyre focusing on staying positive.

We are trading 2017 so we can have the rest of our lives with her, Kevin said.

Continued here:
Gift of Life: Santaquin mom searching for a bone marrow match adds 1200 names to registry - Daily Herald

Last Updated On 10 June,201705:37 pm

Stem cells can be harvested from certain parts of the human body.

(Online) - The Lipogems technology has great promise, but experts say itll take time to assess how successful the new procedure isThe technology is ideal for patients with certain orthopedic conditions, such as painful joints including the knee, ankle, or shoulder with limited range of motion. Additionally, it can be used in soft tissue defects located in tendons, ligaments, and/or muscles to improve the biologic environment, said Dr. Brian Cole, professor of orthopedic surgery, and section head of the Rush Cartilage Restoration Center, in a press release.

They are believed to help the natural regenerative processes in the body.

Hence they have earned the nickname as mini drug stores based on their ability to secrete a spectrum of bioactive molecules and support the natural regeneration of focal injuries.

Stem cells can be harvested from certain parts of the human body, most notably bone marrow and adipose tissue (fat).

Harvesting bone marrow stem cells is a significantly more invasive and time-consuming procedure that is performed using general anesthesia.

Lipogems offers a novel approach to orthopedic stem cell treatments by using a persons own fat.

The procedure uses a small incision into an area of subcutaneous fat, from which a quantity of fat tissue is harvested and processed by the Lipogems apparatus.

The technology itself, which really is the device that processes the fat, creates a concentration of fat that has been cleansed of all the extraneous things like red blood cells and fibrous tissues, Cole told Healthline.

The concentrated stem cells within that fat tissue are then applied to the problematic joint or bone area.

Lipogems offers a streamlined procedure for stem cell treatment, but there is nothing new about the science itself.

The use of stem cells to treat a variety of conditions has been ongoing for some time now.

What were lacking is really good data at this point in the clinical setting, Cole said. There is substantial data in the laboratory suggesting that these cells may function in the way Ive described: reducing inflammation and so forth. But, we really dont have yet much in the way of good solid clinical data saying that definitively this is making a difference.

Instead, he would like those seeking orthopedic treatment to understand that Lipogems is just one part of a much larger and more complex suite of tools used by physicians.

It has to be taken into context of all the other possible treatment options, from simply icing down a swollen ankle, to changing your daily activity, to surgery.

The unfortunate thing is that people think, well this is the solution that can be used instead of, say, a joint replacement and no longer do we need to do surgery, said Cole.

Nothing could be further from the truth.

Nonetheless, Cole and his team are still excited about the possibilities of the Lipogems procedure.

Using a readily available and easily accessible substance like fat as a source of stem cells could have far-reaching implications for procedures in the future.

Were optimistic and intuitively there is a good argument to be made that this is as good or better than any other source of stem cells, said Cole.

Read more here:
New technology uses body fat to help relieve joint pain - DunyaNews Pakistan